Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM057738-005
Application #
3613332
Study Section
Project Start
1985-06-01
Project End
1990-04-30
Budget Start
1987-12-14
Budget End
1988-11-30
Support Year
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Rowinsky, E K; Long, G S; Noe, D A et al. (1997) Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 3:401-7
Rowinsky, E K; Grochow, L B; Sartorius, S E et al. (1996) Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 14:1224-35
Francis, P; Rowinsky, E; Schneider, J et al. (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 13:2961-7
Rowinsky, E K; Noe, D A; Grochow, L B et al. (1995) Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13:1975-84
Rowinsky, E K; Adjei, A; Donehower, R C et al. (1994) Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-203
Rowinsky, E K; Noe, D A; Ettinger, D S et al. (1993) Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res 53:1794-801
Rowinsky, E K; Chaudhry, V; Forastiere, A A et al. (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-20
Monsarrat, B; Alvinerie, P; Wright, M et al. (1993) Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr :39-46
Rowinsky, E K; Conley, B A; Jones, R J et al. (1992) Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia 6:526-34
Grochow, L B; Rowinsky, E K; Johnson, R et al. (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706-13

Showing the most recent 10 out of 16 publications